Decoding the Covid-19 connection with diabetes
A growing base of evidence suggests people are significantly more likely to develop diabetes in the months following a Covid-19 infection, and health systems need to…
By
A growing base of evidence suggests people are significantly more likely to develop diabetes in the months following a Covid-19 infection, and health systems need to…
By Abi MillarThe transition to digital, expedited by the Covid-19 pandemic, has opened up new cybersecurity concerns.
By Abi MillarFerring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.
By Abi MillarWhat exactly is black fungus, and what can be done to combat the rise of this condition alongside Covid-19?…
By Abi MillarWith the UK’s blood plasma donated ban lifted, Abi Millar looks into the risk-benefit analysis of producing plasma domestically.
By Abi MillarThe US Federal Trade Commission has initiated a multilateral working group to ensure that mergers and acquisitions in the…
By Abi MillarThe pandemic has demonstrated the critical need for resilience and agility in pharma supply chains.
By Abi MillarAbi Millar digs into academic-industry collaboration, and how this source of innovation could be better leveraged in the future.
By Abi MillarWhat is at the cutting-edge of regenerative medicine in 2021, and are these complex products ready to break into…
By Abi MillarThank you for subscribing to Pharmaceutical Technology